Table 2.
Known genetic alterations characterizing the NSCLC lines used in the paper. Information about genetic defects were retrieved from the database of the Wellcome Trust Sanger Institute Catalogue Of Somatic Mutations In Cancer COSMIC, https://cancer.sanger.ac.uk/cell_lines)
| Cell line | Hystotype | Mutational status | |||
|---|---|---|---|---|---|
| TP53 | EGFR | KRAS | Other mutations/molecular alterations | ||
| Calu-6 | anaplastic carcinoma | mut | wt | Q61K | JAK1, BRCA1, p16INK4A methylation |
| SK-Lu-1 | adenocarcinoma | mut | wt | G12D | KIT, CSF3R, FLT4 |
| NCI-H1975 | adenocarcinoma | mut | L858R + T790 M | wt | PDGFRA, PIK3CA |
| NCI-H2228 | adenocarcinoma | mut | wt | wt | ALK translocation, PDGFRA, RB |